An antiphospholipid panel looks for immune proteins that can make blood more likely to clot in arteries, veins, or the small vessels of the placenta. The most familiar names on the report are lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies. Despite the word “anticoagulant,” lupus anticoagulant is usually linked with clotting risk in the body, not protection from clots. Anticardiolipin antibodies are measured as IgG and IgM levels, and their meaning depends on the antibody type, strength, persistence, and the reason the test was ordered.
A single abnormal result does not automatically mean antiphospholipid syndrome. These antibodies can appear temporarily after infection, inflammation, pregnancy, some medications, or acute illness. The result becomes more concerning when it is clearly positive, still positive at least 12 weeks later, and occurs in someone with a clot, certain pregnancy complications, or other compatible findings.
- A normal antiphospholipid panel is usually negative, meaning lupus anticoagulant is not detected and anticardiolipin and anti-beta-2 glycoprotein I antibodies are below the lab’s positive cutoff.
- Lupus anticoagulant is a functional clotting test, not a direct antibody level, and it can be distorted by heparin, warfarin, direct oral anticoagulants, and acute illness.
- Moderate or high anticardiolipin IgG is more concerning than a weak, isolated IgM result, especially when it persists on repeat testing.
- Persistent positivity means the antibody is present again at least 12 weeks later, which helps separate long-term risk from temporary antibody findings.
- Triple positivity carries the highest risk pattern, meaning lupus anticoagulant plus anticardiolipin plus anti-beta-2 glycoprotein I antibodies are all positive.
- Urgent symptoms such as one-sided leg swelling, chest pain, sudden shortness of breath, stroke-like symptoms, or severe pregnancy symptoms need immediate medical care, regardless of antibody results.
Table of Contents
- What the Antiphospholipid Panel Measures
- How Lupus Anticoagulant and Anticardiolipin Results Are Reported
- Result Patterns That Change Clotting and Pregnancy Risk
- Why Repeat Testing After 12 Weeks Matters
- Anticoagulants and Other Things That Can Distort Results
- How Results Fit With Clots, Pregnancy Loss, and Other Findings
- What to Do After an Abnormal Panel
What the Antiphospholipid Panel Measures
An antiphospholipid panel checks for antibodies that react with phospholipid-binding proteins. Phospholipids are fat-like molecules found in cell membranes and clotting test reagents. The immune system does not usually make clinically important antibodies against these targets. When it does, the antibodies may interfere with clotting tests in the laboratory and, in some people, increase the risk of abnormal clotting in the body.
A standard panel usually includes three main test groups:
- Lupus anticoagulant, often reported through clot-based assays such as dilute Russell viper venom time, lupus-sensitive aPTT, silica clotting time, mixing steps, and phospholipid confirmation.
- Anticardiolipin antibodies, usually reported as IgG and IgM, sometimes with IgA depending on the lab.
- Anti-beta-2 glycoprotein I antibodies, usually reported as IgG and IgM, sometimes with IgA.
These tests are related but not interchangeable. Lupus anticoagulant asks whether the person’s plasma disrupts phospholipid-dependent clotting reactions. Anticardiolipin and anti-beta-2 glycoprotein I tests measure antibody levels more directly, usually by immunoassay.
The panel is most useful when the result is interpreted together with the person’s clinical history. A positive result in someone with an unexplained deep vein thrombosis, pulmonary embolism, stroke at a young age, recurrent pregnancy loss, fetal loss, or severe placenta-related pregnancy complication means more than the same result found during a broad screening test in someone with no symptoms.
The name “lupus anticoagulant” causes confusion. Many people with lupus anticoagulant do not have systemic lupus erythematosus. The word “anticoagulant” comes from the laboratory effect: it can prolong clotting time in a test tube. In the body, however, lupus anticoagulant is often associated with a higher tendency toward thrombosis, which means abnormal clot formation.
When doctors are looking more broadly at unexplained clotting risk, the antiphospholipid panel may be considered alongside other tests, such as protein C, protein S, and antithrombin testing. Those tests look for inherited or acquired anticoagulant protein deficiencies, while antiphospholipid testing looks for immune-mediated clotting risk.
How Lupus Anticoagulant and Anticardiolipin Results Are Reported
Antiphospholipid reports can look complicated because they combine different test methods. A helpful way to read the report is to separate the functional lupus anticoagulant section from the antibody-level sections.
Lupus anticoagulant results
Lupus anticoagulant is usually reported as negative, positive, detected, not detected, indeterminate, or borderline. Some reports include several parts, such as a screening test, mixing test, confirmatory test, normalized ratio, or interpretation comment.
A typical lupus anticoagulant workup asks three questions:
- Is a phospholipid-dependent clotting test prolonged?
Screening tests such as dRVVT or lupus-sensitive aPTT look for delayed clotting in conditions where lupus anticoagulant may interfere. - Does the abnormality correct when normal plasma is added?
A mixing study helps separate factor deficiency from an inhibitor pattern. If the result does not correct well, an inhibitor such as lupus anticoagulant becomes more likely. - Does added phospholipid shorten or correct the clotting time?
Phospholipid confirmation supports lupus anticoagulant because the antibody effect is reduced when excess phospholipid is supplied.
This is why a person may see several abnormal and normal-looking numbers on the same report before the final interpretation. The final laboratory interpretation usually matters more than any one raw value.
Lupus anticoagulant can also overlap with other clotting tests. For example, it may prolong an aPTT result and lead to follow-up testing with an aPTT mixing study. A prolonged aPTT does not prove lupus anticoagulant by itself, because factor deficiencies, heparin, specific factor inhibitors, and sample problems can also prolong clotting time.
Anticardiolipin antibody results
Anticardiolipin antibodies are usually reported by antibody class:
- IgG anticardiolipin
- IgM anticardiolipin
- Sometimes IgA anticardiolipin, depending on the lab and clinical setting
Many reports label the level as negative, low positive, moderate positive, or high positive. Units vary by method, but older and still widely used clinical thresholds often treat results above about 40 GPL or MPL units, or above the lab’s high percentile cutoff, as more meaningful than weak positives. Newer classification systems may separate moderate and high titers, with high levels carrying more weight.
A weak positive anticardiolipin result can happen for many reasons and often does not confirm a disease. In contrast, a moderate or high IgG result that persists and matches a clotting or pregnancy history is more concerning.
IgM results need careful context. Isolated low-level IgM anticardiolipin may be transient or less specific, especially after infection or inflammation. That does not mean IgM is always irrelevant, but it should not be overread without repeat testing and clinical correlation.
Anti-beta-2 glycoprotein I results
Anti-beta-2 glycoprotein I antibodies are often part of the same panel because beta-2 glycoprotein I is a major target in antiphospholipid syndrome. These are also usually reported as IgG and IgM. Like anticardiolipin antibodies, stronger and persistent results are generally more concerning than isolated weak positives.
Anti-beta-2 glycoprotein I testing helps clarify risk because some people have this antibody even when anticardiolipin is negative, and some have both. A pattern with multiple positive antibody types is usually more important than one borderline result.
| Test | What it checks | How it is often reported | Why it matters |
|---|---|---|---|
| Lupus anticoagulant | Functional interference with phospholipid-dependent clotting | Positive, negative, indeterminate, or detected/not detected | Often the strongest lab marker for thrombotic risk when persistent |
| Anticardiolipin IgG/IgM | Antibodies against cardiolipin-associated targets | Negative, low, moderate, or high; sometimes numeric units | More meaningful when moderate/high and persistent |
| Anti-beta-2 glycoprotein I IgG/IgM | Antibodies against beta-2 glycoprotein I | Negative, low, moderate, or high; sometimes numeric units | Adds specificity and helps define higher-risk profiles |
Result Patterns That Change Clotting and Pregnancy Risk
Antiphospholipid results are not all equal. The risk suggested by the panel depends on which tests are positive, how strong they are, whether they persist, and whether the person has a matching clinical event.
The highest-risk lab pattern is often called triple positivity. This means:
- Lupus anticoagulant is positive.
- Anticardiolipin antibody is positive.
- Anti-beta-2 glycoprotein I antibody is positive.
Triple positivity suggests a more persistent and clinically important antibody profile. It is more concerning than a single weak antibody result, especially in someone who has already had a clot or a pregnancy complication linked to antiphospholipid syndrome.
Double positivity means two of the main antibody groups are positive. This can also be meaningful, especially when one of the positive tests is lupus anticoagulant or when antibody titers are moderate or high.
Single positivity means only one antibody group is positive. This pattern is more mixed. Persistent lupus anticoagulant alone can be important. Persistent moderate or high IgG anticardiolipin or anti-beta-2 glycoprotein I can also matter. A one-time, low-positive anticardiolipin IgM result is much less specific.
Antibody strength matters. A report that says “low positive” or “borderline” should not be treated the same way as a strong positive. Low-level antibodies can appear temporarily after viral illness, bacterial infection, vaccination, inflammation, or other immune stimulation. Some medications and autoimmune conditions can also be associated with positive antibodies.
The clinical setting also changes the meaning. A positive panel after an unprovoked pulmonary embolism is interpreted differently from a weak positive found during general wellness testing. When a clot is suspected, tests such as D-dimer, imaging, and clinical exam guide urgent evaluation; antibody tests do not rule a clot in or out in the moment.
A useful risk-reading approach is:
- Most concerning: persistent lupus anticoagulant, triple positivity, high-titer IgG antibodies, or recurrent thrombotic/pregnancy events.
- Intermediate concern: persistent double positivity, moderate-titer IgG, or persistent single positivity with a strong clinical history.
- Lower concern: isolated low-titer IgM, borderline values, one-time positivity during illness, or positive results with no compatible clinical history.
This does not replace medical judgment. Some people with high-risk results never develop a clot, and some people with clots have negative antiphospholipid tests. The panel adds evidence; it does not predict the future with certainty.
Why Repeat Testing After 12 Weeks Matters
Repeat testing is one of the most important parts of interpreting an antiphospholipid panel. A result that is positive once may not stay positive. For antiphospholipid syndrome, persistence is usually defined as a positive result again at least 12 weeks after the first positive test.
The 12-week interval helps avoid overdiagnosis. Short-lived antibodies can appear after infections and other immune triggers. If testing is repeated too soon, the same temporary immune response may still be present. Waiting at least 12 weeks gives a better sense of whether the antibody pattern is durable.
Repeat testing should generally use the same main antibody categories:
- Lupus anticoagulant
- Anticardiolipin IgG and IgM
- Anti-beta-2 glycoprotein I IgG and IgM
A repeat result is most persuasive when the same type of abnormality persists. For example, moderate or high anticardiolipin IgG on two tests at least 12 weeks apart is more meaningful than a low IgM result on the first test and a different borderline result later.
Timing also matters because acute clotting events can complicate interpretation. Someone who just had a clot may already be receiving heparin, warfarin, or a direct oral anticoagulant. These drugs can interfere with lupus anticoagulant testing. In that setting, doctors may focus first on treating the clot and plan repeat antibody testing later under better conditions.
Classification criteria are often mentioned in reports or specialist notes. These criteria were designed to make research studies more consistent, not to replace diagnosis by a clinician. In everyday care, doctors consider the full picture: symptoms, imaging, pregnancy history, medication exposure, autoimmune disease, family history, and repeat lab results.
A negative repeat test can be reassuring, especially if the first result was weak or occurred during illness. It may mean the first result was transient. A persistently positive result does not automatically mean treatment is needed forever, but it does deserve a careful discussion of clot history, pregnancy plans, risk factors, and medication choices.
Anticoagulants and Other Things That Can Distort Results
Lupus anticoagulant testing is sensitive to anticoagulant medications because it uses clotting time. Anticardiolipin and anti-beta-2 glycoprotein I immunoassays are usually less affected by anticoagulants, but the overall panel can still be hard to interpret when the person is acutely ill or already being treated for a clot.
Medications that can interfere include:
- Unfractionated heparin
- Low-molecular-weight heparin
- Warfarin
- Direct oral anticoagulants, such as apixaban, rivaroxaban, edoxaban, and dabigatran
Direct oral anticoagulants are a common cause of misleading lupus anticoagulant results. They can make clot-based assays look positive or indeterminate even when true lupus anticoagulant is absent. Some laboratories use drug-neutralizing methods or additional drug-level checks, but these approaches have limits. The lab’s comment section may say whether anticoagulant interference is suspected.
Warfarin adds another problem because it lowers vitamin K-dependent clotting factors and changes baseline clotting times. A patient on long-term warfarin may also be having INR monitoring, which serves a different purpose from antibody testing. For a deeper explanation of warfarin monitoring, INR and warfarin interpretation focuses on treatment intensity rather than antiphospholipid antibody diagnosis.
Other factors can also affect results:
- Recent thrombosis
- Acute infection
- High inflammation
- Pregnancy or the postpartum period
- Recent surgery or hospitalization
- Poor sample handling
- Very high C-reactive protein in some assay systems
- Other clotting factor abnormalities
None of these automatically invalidates the panel. They simply raise the chance that the result needs repeat testing, careful lab interpretation, or specialist input.
Preparation is usually simple. Fasting is not usually required. The most important step is to tell the ordering clinician and lab about anticoagulants, aspirin, pregnancy, recent infections, recent clots, autoimmune diagnoses, and any previous antiphospholipid results. Stopping an anticoagulant just to improve test accuracy can be dangerous and should never be done without the prescribing clinician’s instructions.
How Results Fit With Clots, Pregnancy Loss, and Other Findings
Antiphospholipid antibodies matter most when they match a clinical pattern. The major patterns are thrombosis and specific pregnancy complications, but there are other clues that may support the diagnosis or change risk assessment.
Venous and arterial clots
Venous clots include deep vein thrombosis and pulmonary embolism. A deep vein thrombosis often causes one-sided leg swelling, pain, warmth, or redness. A pulmonary embolism may cause sudden shortness of breath, chest pain, coughing blood, fainting, or fast heart rate.
Arterial clots can cause stroke, transient ischemic attack, heart attack, or limb ischemia. Stroke-like symptoms include face drooping, arm weakness, speech trouble, sudden vision loss, severe dizziness, or sudden numbness on one side of the body. These symptoms need emergency evaluation.
Antiphospholipid testing is often considered when a clot is unprovoked, occurs at a younger age, recurs, appears in an unusual site, or happens with autoimmune features. The panel may also be ordered when routine clotting tests show an unexplained pattern, such as prolonged aPTT. A broader coagulation panel can show clotting-time abnormalities, but it cannot diagnose antiphospholipid syndrome by itself.
Pregnancy complications
Antiphospholipid antibodies can affect pregnancy by contributing to placental clotting, inflammation, and poor placental function. Testing may be considered after recurrent early pregnancy loss, fetal death, severe preeclampsia, fetal growth restriction, or preterm delivery due to placental disease.
Not every miscarriage is related to antiphospholipid antibodies. Early pregnancy loss is common and has many causes, including chromosome abnormalities. Testing is more informative when the pregnancy history fits recognized patterns and antibody results are persistent.
Pregnancy planning deserves special care for anyone with known antiphospholipid antibodies, previous clots, or previous antiphospholipid-related pregnancy complications. Treatment decisions may involve obstetrics, maternal-fetal medicine, hematology, and rheumatology. Low-dose aspirin and heparin-based strategies are used in some situations, but the right plan depends on prior thrombosis, pregnancy history, antibody profile, and bleeding risk.
Platelets and other lab clues
Some people with antiphospholipid syndrome have mild thrombocytopenia, which means a low platelet count. This can seem confusing because the condition is associated with clotting, not just bleeding. A low platelet count can occur from immune platelet destruction or platelet activation, while clotting risk may still be present.
Platelets should be interpreted with the rest of the blood count. A platelet count result helps show whether thrombocytopenia is mild, moderate, or severe and whether other blood cell lines are also abnormal.
Other possible associated findings include livedo reticularis, heart valve thickening, kidney involvement, migraine-like symptoms, and autoimmune disease such as lupus. These findings are not enough to diagnose antiphospholipid syndrome alone, but they may influence the level of concern when antibody results are persistent.
What to Do After an Abnormal Panel
The next step after an abnormal antiphospholipid panel depends on the result pattern and the reason the test was ordered. The response should be different for a person with a new pulmonary embolism than for someone with a low-positive antibody found during screening.
Start by identifying the exact abnormality:
- Was lupus anticoagulant positive, negative, or indeterminate?
- Were anticardiolipin antibodies IgG, IgM, or both?
- Were anti-beta-2 glycoprotein I antibodies IgG, IgM, or both?
- Were the antibody levels low, moderate, or high?
- Was the person taking anticoagulants at the time?
- Was the test done during infection, pregnancy, acute clotting, or hospitalization?
Next, check whether repeat testing is planned. If the result is new, repeating the panel at least 12 weeks later is often necessary before labeling it persistent. The repeat timing may need adjustment if the person is on anticoagulation or has recently had an acute event.
For people with a clot, treatment usually focuses first on the clot itself. Imaging, clot location, bleeding risk, provoking factors, and medication history drive immediate decisions. Antiphospholipid results may influence long-term anticoagulant choice and duration, especially in high-risk profiles such as persistent lupus anticoagulant or triple positivity.
For people without a clot, an abnormal panel does not always mean preventive blood thinners are needed. Doctors often address modifiable risk factors instead: smoking, estrogen-containing medications, dehydration during travel, surgery planning, immobility, uncontrolled blood pressure, diabetes, and high cardiovascular risk. Aspirin or anticoagulation decisions should be individualized.
For pregnancy planning, do not wait until late pregnancy to discuss known positive results. A preconception visit gives the care team time to review prior results, repeat the panel if needed, assess clot history, and plan monitoring.
Seek urgent care now, rather than waiting for repeat antibody testing, if symptoms suggest an active clot or stroke. Warning signs include sudden shortness of breath, chest pain, coughing blood, fainting, one-sided leg swelling, sudden weakness, speech trouble, severe new headache with neurologic symptoms, or sudden vision changes. During pregnancy, severe headache, vision changes, severe abdominal pain, heavy bleeding, or reduced fetal movement also needs prompt medical attention.
References
- The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria 2023 (Classification Criteria)
- An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies 2025 (Guideline)
- Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation 2020 (Guideline)
- Testing for the lupus anticoagulant: the good, the bad, and the ugly 2024 (Review)
- Clinical and Laboratory Diagnosis of Antiphospholipid Syndrome: A Review 2024 (Review)
- EULAR recommendations for the management of antiphospholipid syndrome in adults 2019 (Guideline)
Disclaimer
Antiphospholipid antibody results can be difficult to interpret, especially during acute illness, pregnancy, or anticoagulant treatment. This information is for education and should not be used to diagnose antiphospholipid syndrome, start aspirin, stop anticoagulants, or change pregnancy treatment without a clinician’s guidance. Seek urgent medical care for symptoms of a blood clot, stroke, pulmonary embolism, or serious pregnancy complication.
